Introduction
============

Urotensin II (UII) was first isolated in the 1960s from a goby fish indigenous to the Californian coastline. Since, it has been identified as an 11 amino acid peptide derived from larger 124 (alpha) and 139 (gamma) amino acid prepro-UII encoded by a single gene (Ames et al., [@B2]). It is expressed in species ranging in the evolutionary levels, all isoforms having a conserved cyclic hexapeptide core-sequence motif of CFWKYC (Colton et al., [@B20]). UII binds to the Gq protein urotensin II receptor, UT, known originally as the orphan GPR14 receptor (Ames et al., [@B2]). This receptor has been identified in varying quantities (Maguire et al., [@B63]) in cardiac myocytes, vascular smooth muscled cells (SMC), endothelial cells, spinal cord, central nervous system (CNS), and kidneys (Ames et al., [@B2]; Liu et al., [@B61]; Matsushita et al., [@B67]; Maguire et al., [@B64]; Zhu et al., [@B112]). UII, on the other hand, has been detected by immunohistochemistry in blood vessels from the heart, pancreas, kidney, placenta, thyroid, adrenal gland, and umbilical cord, as well as in human epithelial cells of the kidneys (Shenouda et al., [@B83]; Silvestre et al., [@B86]; Zhu et al., [@B112]). Both ligand and receptor seem to be ubiquitously expressed in human tissues (Douglas et al., [@B29]), though lymphocytes and macrophages, respectively, are the largest producers of UII and UT in sites of atherosclerotic lesions (Bousette et al., [@B13]).

Urotensin II has been defined as the most potent vasoconstrictor to date as it is approximately 10-fold more potent than ET-1 (Ames et al., [@B2]). Yet, stimulation of UT can also trigger the release of nitric oxide (NO), prostacyclin, prostaglandin E~2~, and endothelium-derived hyperpolarizing factors to balance the contractile effect on SMCs (Gibson, [@B38]; Bottrill et al., [@B9]; Douglas and Ohlstein, [@B31]; Katano et al., [@B51]; MacLean et al., [@B62]; Gray et al., [@B39]; Camarda et al., [@B15]; Zhang et al., [@B109]; Ishihata et al., [@B48]; Gardiner et al., [@B37]; Lacza and Busija, [@B54]). Vasoconstriction is mediated by receptors on SMCs, whereas vasodilation is endothelium-mediated (Douglas et al., [@B29]). However, in a disease state of chronic heart failure or essential hypertension, UII loses its dilatory ability (Lim et al., [@B60]; Sondermeijer et al., [@B89]). It is understood that such a loss and dysfunction of endothelial cells would favor a contractile response over a relaxant one (Lim et al., [@B60]). Hence, UII causes endothelium-independent vasoconstriction and endothelium-dependent vasodilation. In fact, the contractile response of rat aorta UII decreased from 79 to 33% in the presence of the endothelium (Bottrill et al., [@B9]; Ishihata et al., [@B49]). The complex and contrasting vascular action of UII is not only dependent on the condition of the endothelium, but also on the vascular bed type and species (Douglas et al., [@B28], [@B32]).

In a healthy human, UII functions as a chronic regulator of vascular tone rather than influencing regions in a phasic manner (Douglas and Ohlstein, [@B31]). Its "pseudo-irreversible" binding properties and slow dissociation rate from the UT receptor leads to prolonged activation of UT and to a functionally silent system (Douglas et al., [@B29],[@B30]). In patients with cardiovascular disease, this state of equilibrium is disturbed as they experience an upregulation of UT (Douglas et al., [@B32]) and of UII in atherosclerotic lesions (Ames et al., [@B2]; Maguire et al., [@B64]; Hassan et al., [@B43]) resulting in vasoconstriction. Elevated plasma UII levels are found in patients with heart failure (Douglas et al., [@B32]; Ng et al., [@B68]; Richards et al., [@B75]; Russell et al., [@B77]; Lapp et al., [@B57]), congestive heart failure (Douglas et al., [@B32]; Richards et al., [@B75]), carotid atherosclerosis, renal failure (Totsune et al., [@B97]), renal dysfunction (Totsune et al., [@B100]), portal hypertension-cirrhosis (Heller et al., [@B44]), diabetes mellitus (Totsune et al., [@B98]), and essential hypertension (Matsushita et al., [@B67]; Cheung et al., [@B17]; Suguro et al., [@B94]). Although UII levels are always higher in patients than controls, higher levels can also correlate with a decreased chance of adverse outcome, suggesting a protective role (Khan et al., [@B52]). In fact, some suggest that UII can counteract sympathetic and natriuretic cardiovascular risk factors (Mallamaci et al., [@B66]), and have a restorative effect on endothelial function (Zoccali et al., [@B113]).

Pathology and Pathophysiology
=============================

Urotensin II acts as a mitogenic and hypertrophic agent resulting, in part, in the enlargement of cells and in the reorganization of sarcomeres. These cellular responses result from UT receptor-binding which promote tyrosine phosphorylation of epidermal growth factor (EGF) receptor and in turn activate mitogen-activating protein kinases (MAPK), extracellular signal-regulated kinase 1/2 (ERK 1/2), and p38 (Sauzeau et al., [@B81]; Zou et al., [@B114]; Tamura et al., [@B96]; Onan et al., [@B69]). UII also increases cell proliferation in vascular SMCs (Sauzeau et al., [@B81]; Watanabe et al., [@B104],[@B105]; Tamura et al., [@B96]) by acting synergistically with oxidized low-density lipoproteins (LDL), amongst several other mitogens (Watanabe et al., [@B104],[@B105], [@B106]). In addition, the remodeling process is affected by the UII-induced release of inflammatory cytokines such as interleukin-6 (IL-6) from cardiomyocytes (Sano et al., [@B80]; Tzanidis et al., [@B102]; Johns et al., [@B50]; Russell and Molenaar, [@B78]). Procollagen, an integral part of myocardial remodeling, is also upregulated in fibroblasts by UII activation of TGF-β1 (Tzanidis et al., [@B102]; Dai et al., [@B21]). Such pro-fibrotic effects lead to cellular hypertrophy, protein synthesis, and the expression of natriuretic factors, all induced by UII (Tzanidis et al., [@B101], [@B102]; Zou et al., [@B114]). UII has also been shown to increase expression of NADPH oxidase and plasminogen activator inhibitor-1 (PAI-1) in vascular SMCs (Djordjevic et al., [@B26]), likely leading to hypoxia-induced hypertension and atherosclerosis (Pakala, [@B71]). Hence, UII might be involved in the etiology of heart failure (Douglas et al., [@B32]; Ng et al., [@B68]; Richards et al., [@B75]) and might contribute to the development of essential (Matsushita et al., [@B67]) and secondary (Heller et al., [@B44]) hypertension via remodeling of the vasculature.

Cardiovascular disease
----------------------

Endothelial cell dysfunction causes vasoconstriction or inadequate vasodilation resulting in myocardial ischemia and hypertension (Zhang et al., [@B110]; Wang et al., [@B103]; Zhou et al., [@B111]; Russell and Molenaar, [@B78]), associated with an increase in UII and UT. In fact, there is a 3.4-fold increase of the UII system in patients with hypertension (Suguro et al., [@B94]). There is also a positive correlation between the extent of congenital heart failure (CHF) and plasma UII levels (Ng et al., [@B68]; Richards et al., [@B75]; Douglas, [@B27]; Russell et al., [@B77]; Lapp et al., [@B57]; Gruson et al., [@B41]). hUII plasma concentration in 88 patients with heart failure was shown to be 2.1-fold higher compared to 74 age-matched controls (Richards et al., [@B75]). In children with CHF, the plasma hUII plasma level was also significantly elevated (Simpson et al., [@B88]). It has been suggested that the upregulation of myocardial hUII may contribute to impaired myocardial function under disease conditions such as CHF (Hassan et al., [@B42]), as in high concentrations, hUII leads to a collapse of the cardiovascular system and death in primates due to a dramatic reduction of heart rate, mean blood pressure, first-order derivative of left ventricular pressure, and carotid and coronary blood flow (Ames et al., [@B2]). UII is also correlated with left ventricular end-diastolic dimensions and negatively correlated with the left ventricular ejection fraction (Douglas et al., [@B32]; Gruson et al., [@B41]). Increased expression of UII and UT has also been associated with human coronary atherosclerosis (Maguire et al., [@B64]; Hassan et al., [@B43]), left ventricular hypertrophy, and fibrosis (Hunt et al., [@B46]).

Urotensin II is upregulated in regions of macrophage infiltration at atherosclerotic lesions (Bousette et al., [@B13]). It may thus accelerate the development of atherosclerosis in hypertensive patients by acting synergistically with mildly oxidized-LDL and inducing proliferation of vascular SMCs (Watanabe et al., [@B104],[@B105]). The formation of foam cells is another key feature of atherosclerosis affected by an upregulation in UII which increases acyl-coenzyme A:cholesterol acyltransferase-1 (ACAT-1) expression in macrophages (Watanabe et al., [@B107]). UII may also play a role in myocardial fibrogenesis as it increases procollagen and fibronectin synthesis in rat fibroblasts (Zou et al., [@B114]). A significant increase of 23 ± 2% of collagen peptide synthesis was observed in rats with heart failure with elevated levels of UII and UT (Tzanidis et al., [@B102]; Russell and Molenaar, [@B78]). UII is also upregulated in myointimal cells and induces extracellular matrix deposition contributing further to the vascular remodeling associated with restenosis (Rakowski et al., [@B74]). In addition, a significant increase in UII-dependent activation of hypertrophic signals was observed in cardiomyocytes (Zou et al., [@B114]; Tzanidis et al., [@B102]; Johns et al., [@B50]; Onan et al., [@B69]). The use of UT antagonists on animal models of cardiovascular disease has led to improvements in hemodynamics and cardiovascular remodeling, suggesting that UII is involved in the development of disease. The heart is one of the tissues with the highest UT expression (Ames et al., [@B2]), further supporting its role in cardiovascular physiology (Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}).

![**Schematic representation of the potential role of UII in the pathogenesis of atherosclerosis**. The high-fat diet associated with a Western lifestyle results in the upregulation of UII and the UT receptor expression. UII is known to inhibit insulin release and may contribute to the development of the metabolic syndrome. The resulting inflammation and endothelial damage leads to kidney injury which in turn increases blood pressure. Cardiovascular disease ensues by the formation of the atherosclerotic plaques. SMC proliferate and macrophages infiltrate at these lesions, enhanced by ACAT-1 activity.](fphar-02-00038-g001){#F1}

![**Summary schematic of the effects of UII in endothelial cells, vascular SMCs, and macrophages**. Stimulation of UT with UII induces phosphorylation of EGF receptor and activation of ERK1/2 and p38 pathways leading to mitogenic changes in SMCs and an increase in IL-6, PAI-1, and ACAT-1. Furthermore, stimulation of NADPH Oxidase increases cell adhesion molecule expression promoting macrophage infiltration in atherosclerotic vessels. UII binding to macrophage UT increases macrophage ACAT-1 resulting in increased lipid uptake and subsequent foam cell production.](fphar-02-00038-g002){#F2}

Metabolic syndrome
------------------

In addition to affecting vascular tone and cardiac health, UII also has a role in insulin secretion and the pathogenesis of type II diabetes mellitus (DMII; Figure [3](#F3){ref-type="fig"}). Both UII and UT are present in the human pancreas and seem to directly inhibit beta cell function, thus inhibiting insulin release (Ames et al., [@B2]; Silvestre et al., [@B87]; Elshourbagy et al., [@B35]). In fact, UII levels have been reported to be 1.7-fold higher in diabetic patients than in healthy controls. However, UII levels did not correlate with fasting blood sugar levels demonstrating that hyperglycemia is not responsible for UII increase. It has been suggested that elevated UII plasma concentrations in metabolic syndrome may be a result of damaged endothelial cells, as is the case in cardiovascular diseases (Totsune et al., [@B97]). The metabolic syndrome, which includes DMII, is associated with increased inflammatory cytokines and elevated free fatty acids across its spectrum (Bergman and Ader, [@B7]; Saltiel and Kahn, [@B79]; Rajala and Scherer, [@B73]; Wellen and Hotamisligil, [@B108]). In fact, UII can upregulate IL-6 which plays a role in atherogenesis and hypertrophy, as well as in insulin resistance (Fernandez-Real and Ricart, [@B36]; Johns et al., [@B50]). Insulin resistance may further impair vasodilation, as plasma insulin levels and blood pressure are correlated in patients with hypertension (Sowers, [@B91]). Interestingly, several SNPs identified on the hUII gene have been associated with insulin resistance and therefore with a susceptibility to DMII (Totsune et al., [@B97]; Suzuki et al., [@B95]). In addition, DMII patients with renal dysfunction exhibited plasma and urine UII levels higher than in patients with normal function (Totsune et al., [@B98]). These elevated levels are probably due to an increased production of UII in renal tubular cells as a result of renal damage (Matsushita et al., [@B67]; Totsune et al., [@B97]). In effect, insulin resistance causes increased blood pressure and consequently results in atherosclerosis and renal damage (El-Atat et al., [@B34]).

![**Summary schematic of the effects of UII on the metabolic syndrome**. In addition to the cardiorenal aspects influenced by urotensin, UII increases circulating levels of inflammatory cytokines, including IL-6, resulting in insulin resistance. It further acts directly on the pancreas to decrease beta cell secretion.](fphar-02-00038-g003){#F3}

Renal disease
-------------

In 2003, a joint publication by a panel of nephrologists and cardiologists demonstrated the importance of kidney disease as a risk factor for the development of cardiovascular disease (Tölle and van der Giet, [@B99]). The kidney plays an important role in controlling cardiovascular homeostasis, influencing both cardiac preload and afterload, and regulating vasomotor tone (Douglas et al., [@B29]). The kidneys are a major source of UII and UT and due to either a reduced renal clearance or increased renal UII production (Figure [4](#F4){ref-type="fig"}). Urinary concentrations of UII are significantly increased with renal tubular disease (Matsushita et al., [@B67]). In comparison to controls, patients with chronic renal failure had a two-fold increase in hUII-like immunoreactivity concentrations (Bohm and Pernow, [@B8]), and in patients with diabetic nephropathy, biopsies revealed a 45-fold increase in UII and a 2000-fold increase in UII receptors (Langham et al., [@B56]). Bolus injections of rat UII in the low pmol/100 g body weight range have actually demonstrated dose-related reductions in glomerular filtration rate (GFR), urine flow, and sodium excretion rate (Song et al., [@B90]). However, other studies saw only a modest reduction in GFR and no change in sodium excretion (Ovcharenko et al., [@B70]). Such discrepancies may be explained by a lack of consistency in experimental design and of consensus on methods.

![**Summary schematic of the effects of UII in the renal tubules and glomerulus**. Urotensin and possibly urotensin-related protein binding to UT in renal tubule cells results in decreased urine flow. In addition, UII acting at the glomerulus directly decreases glomerular filtration rate. These effects impair normal cardiovascular homeostasis, increasing blood pressure, and promoting cardiovascular disease.](fphar-02-00038-g004){#F4}

For example, renal UT receptors, the majority of which are found in the renal medulla (Disa et al., [@B25]), have been shown to also bind the urotensin-related peptide (URP; Ashton, [@B3]). If the URPs that bind to UT actually stimulate the receptor, then many UII-like immunoreactivity studies may have considerably underestimated the significance of the UII system in regulating a variety of pathophysiological conditions (Russell, [@B76]). All methods have the risk of including or excluding precursor molecules and metabolites of UII that may or may not be active. Antibody-based methods are not specific for hUII and detect hUII metabolites as well. In fact, there is currently no consensus on a reliable method to measure plasma hUII (Tölle and van der Giet, [@B99]). Regardless of the method, when measuring plasma UII concentrations, it is important to exclude individuals with co-existing diseases associated with elevated UII concentrations. When working with animal models, it is important to consider that UII from different species induce different effects in identical physiological models (Li et al., [@B59]). The contrary is also true when considering the varying effects of hUII in rats, C57/B18 mice, pigs, cynomolgus monkeys, and marmosets (Douglas et al., [@B28]). The UII source and animal model must also be considered working with isolated vessels, as well as the choice of vessel segment (Camarda et al., [@B15]). The lack of consensus in methods and models has lead to many conflicting reports on the effects of UII in numerous disease states including cardiovascular disease, metabolic syndrome, and renal disease. The lack of a proper pathway is in part due to this situation.

Urotensin II is upregulated in a number of disease states. When acute symptoms arise, UII is temporarily upregulated in order to repair the damage caused and it later returns to its normal levels. This would explain how the upregulation of UII is an inverse predictor of adverse clinical outcome in patients with acute coronary syndromes (Khan et al., [@B52]). A chronic increase of the UII system, on the other hand, can lead to the development of several diseases, namely cardiovascular disease (Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}), metabolic syndrome (Figure [3](#F3){ref-type="fig"}), and renal disease (Figure [4](#F4){ref-type="fig"}). These three disease states are not only interconnected as described above, they also share an instigator in a Western lifestyle consisting of too little exercise and excessive lipid consumption. Such habits lead to central obesity, increased blood pressure, raised triglycerides, and reduced HDL cholesterol, all symptoms of the metabolic syndrome. They are further associated with an increase in UII leading to insulin resistance, inflammation, and endothelial damage, which are themselves independent risk factors for cardiovascular and renal diseases (Grundy et al., [@B40]; IDF Epidemiology Task Force Consensus Group, [@B47]). Endothelial damage in the kidneys upregulates the local UII system causing endothelial-independent vasoconstriction. This is an additional source of pressure load to that already caused by a poor lifestyle. Increased blood pressure and resulting plaque formation leads to diseased arteries (Heller et al., [@B44]; Cheung et al., [@B17]; Lapp et al., [@B57]; Balat et al., [@B4]; Suguro et al., [@B94]). Ensuing arterial lesions attract monocytes which interact with oxidized-LDL to form macrophages and foam cells. UII increases acetyl-LDL-induced cholesterol ester accumulation in macrophages to ACAT-1, increasing the amount of foam cells. Interestingly, the lymphocytes and macrophages already at the lesion are respectively the largest producers of UII and UT receptors (Bousette et al., [@B13]). This increase of the UII system at atherosclerotic lesions results in further lesion formation by inducing SMC growth and migration, collagen production, foam cell formation (Watanabe et al., [@B107]). The cycle perpetuates itself in the heart, kidney, and pancreas as long as excess lipid is present in the system. A recent study suggests that a UT receptor gene knock-out has decreased lipid uptake and storage due to the downregulation of lipoprotein uptake receptors and the attenuation of ACAT activity (Bousette et al., [@B10]). This suggests that in an attempt to regulate elevated lipid levels, the UII system is upregulated to increase the amount of available lipid receptors. The increased lipid uptake by hepatocytes will influence metabolic syndrome as the liver is the main source of glycogen. On the other hand, the upregulation of ACAT-1 in hepatocytes will increase the release of LDL, and in macrophages it will increase the formation of foam cells along with this same increased LDL.

Antagonists
===========

In hopes of a new treatment for cardiovascular disease, metabolic syndrome, and renal disease, the altered UII system in disease states has prompted the development of a number of UT receptor antagonists (Table [1](#T1){ref-type="table"}). Several peptide antagonists share a common cyclic region, similar to the conserved region of UII. One of these compounds, urantide, acts as a competitive antagonist, selectively blocking UII-induced effects in the rat aorta (Patacchini et al., [@B72]). It significantly inhibited UII-induced ACAT-1 upregulation in cultured human monocyte-derived macrophages (Watanabe et al., [@B107]). However, urantide has been reported to act as an agonist in cells overexpressing recombinant human UT receptors (Camarda et al., [@B16]). Another peptide UT receptor antagonist, BIM-23127, is competitive for the rat UT receptor (Behm et al., [@B5]) and a full agonist at the recombinant hUT receptor (Herold et al., [@B45]). BIM-23127 inhibited calcium mobilization in human embryonic kidney cells expressing UT receptors (Herold et al., [@B45]), and inhibited UII-induced hypertrophy in cultured H9c2 cardiomyocytes (Johns et al., [@B50]). While the data generated with BIM-23127 should be interpreted cautiously because of its roughly equal affinity for the neuromedin B receptor (Lach et al., [@B53]), it nonetheless represents the most potent UT receptor antagonist characterized to date (Herold et al., [@B45]).

###### 

**Clinical findings, dosages, and affinities of current UT antagonists**.

                                                                                    Type                                                                 Study                                                        Dosage                          Findings                                                                        UT affinity
  --------------------------------------------------------------------------------- -------------------------------------------------------------------- ------------------------------------------------------------ ------------------------------- ------------------------------------------------------------------------------- ----------------------------------------------------------------------
  Urantide                                                                          Competitive antagonist                                               Patacchini et al. ([@B72])                                   0.1 nM--10 μM                   Effects on rat aorta                                                            p*K*~i~ = 8.3 (Patacchini et al., [@B72])
                                                                                                                                                         Watanabe et al. ([@B107])                                    25 nM                           Inhibition of ACAT-1 upregulation, macrophages                                  
                                                                                                                                                         Camarda et al. ([@B16])                                      10 nM, 100 nM, 1000 nM, 10 μM   Agonist activity, overexpression of UT                                          
  BIM-23127                                                                         Competitive antagonist                                               Herold et al. ([@B45])                                       33 nM--3.3 μM                   Inhibited Ca^2+^ mobilization, embryonic kidney cells                           p*K*~i~ = 6.7 (Herold et al., [@B45])
                                                                                                                                                         Johns et al. ([@B50])                                        3 μM                            Inhibited cardiomyocyte hypertrophy                                             
  SB-611812                                                                         Non-peptide competitive antagonist[\*](#tfn1){ref-type="table-fn"}   Rakowski et al. ([@B74])                                     30 mg/kg/day                    Reduced induced intimal hyperplasia                                             *K*~i~ = 121 nM (Rakowski et al., [@B74])
                                                                                                                                                         Bousette et al. ([@B12])                                     30 mg/kg/day                    Improved CHF                                                                    
                                                                                                                                                         Tzanidis et al. ([@B102])                                    30 mg/kg/day                    Reduced remodeling (CHF)                                                        
                                                                                                                                                         Bousette et al. ([@B12])                                     30 mg/kg/day                    Reduced fibrosis                                                                
  Palosuran (ACT-058362)                                                            Non-peptide competitive antagonist                                   Clozel et al. ([@B18])                                       10 mg/kg h                      Reduced Ca^2+^ influx, inhibits MAPK phosphorylation, improved renal function   *K*~i~ = 5 nM (Behm et al., [@B6])[\*\*](#tfn2){ref-type="table-fn"}
                                                                                                                                                         Clozel et al. ([@B19])                                       300 mg/kg/day                   Increased survival, improved metabolic syndrome                                 
                                                                                                                                                         Sidharta et al. ([@B85])[^†^](#tfn3){ref-type="table-fn"}    125 mg bid                      Improvement of diabetic nephropathy, microalbuminuria                           
                                                                                                                                                         Sidharta et al. ([@B84])[^††^](#tfn4){ref-type="table-fn"}   125 mg bid                      No effect on insulin secretion, sensitivity, glucose levels in DMII             
  Piperazino-isoindolinone based antagonist (7a)[^‡^](#tfn5){ref-type="table-fn"}   Non-peptide U-II antagonist                                          Lawson et al. ([@B58])                                       10 mg/kg                        Reduction of ear pinna temperature                                              *K*~i~ = 4.0 nM (Lawson et al., [@B58])

\**No agonist activity (Bousette et al., [@B12])*.

\*\**Low binding in non-primates (*K*~i~ \> 1.0 μM; Behm et al., [@B6])*.

^†^*n = 19, no control group, continuation of medications (ACE, ARBs; Sidharta et al., [@B85])*.

^††^*n = 20 (Sidharta et al., [@B84])*.

^‡^*Oral bioavailability needs improvement (Lawson et al., [@B58])*.

SB-611812
---------

The non-peptide antagonist SB-611812 is highly selective for the UT receptor and is devoid of any agonist activity, which has been a hindrance with previous UT antagonists (Bousette et al., [@B11]). It attenuates UII-induced intimal hyperplasia in a rat model of balloon angioplasty-mediated restenosis. Rats treated with SB-611812 (30 mg/kg/day) following balloon angioplasty had 60% less intimal thickening than vehicle-treated animals (Rakowski et al., [@B74]). These results raise the possibility that UII antagonists may play a role in preventing post-angioplasty arterial stenosis. In addition, Bousette et al. ([@B11]) demonstrated that SB-611812 attenuates cardiac dysfunction in a rat model of CHF induced by coronary ligation. In this study, rats underwent an 8-week ligation of the left anterior descending coronary artery or sham surgery, and were treated with SB-611812 (30 mg/kg/day) or vehicle for 8 weeks. Those treated with the UT antagonist had significantly reduced mortality and improved CHF compared to controls. In fact, the treatment decreased hypertrophy by 54%, ventricular dilatation by 79%, pulmonary edema by 71%, left ventricular end-diastolic pressure by 72%, right ventricular systolic pressure by 92%, and central venous pressure by 59%. This demonstrates not only that UII plays an important role in cardiovascular function, but also that blocking UT receptors can decrease mortality and improved cardiac function. With the same rat CHF model and treatment regimen, Bousette et al. ([@B11]) also demonstrated that SB-611812 can reduce interstitial fibrosis and remodeling following CHF. UII has been shown in the past to have pro-fibrotic effects as it induces collagen type I and type II, as well as fibronectin in fibroblasts (Tzanidis et al., [@B102]). As predicted, blocking UT with SB-611812 decreased myocardial and endocardial fibrosis and reduced collagen deposition resulting in attenuated cardiac remodeling. Therefore, the antagonist-treated group had improved cardiac function in comparison to controls (Bousette et al., [@B12]). Together, these studies demonstrate an improvement in cardiac function and an attenuation of cardiac remodeling after CHF with the use of SB-611812, further promoting the development of UT receptor antagonists in hopes of ameliorating cardiac health. Although the studies show a potential advantage to UII blockade in humans, caution must be used with the results as only a small number of animals were studied.

Palosuran
---------

ACT-058362, commonly known as palosuran, is another non-peptide UT receptor antagonist with promise in drug development. In radioligand binding experiments using ^125^I-UII in cell and membrane preparations expressing human UT receptor, palosuran interacted competitively and specifically with hUT (Clozel et al., [@B18]). Palosuran inhibits ^125^I-UII binding to hUT in membrane preparations with nearly equal potency as native hUII, but with dramatically lower potency for the rat UT receptor. In intact cells, palosuran also has significantly reduced antagonistic properties compared to membrane preparations. In Chinese hamster ovary (CHO) cells transfected with hUT, palosuran has 100-fold lower inhibitory potency than native UII and CHO cells transfected with rat UT, has very low efficacy. Nevertheless, in hUT and rat UT transfected cells, palosuran inhibits UII-induced calcium influx in a dose-dependent manner. It also has the ability to inhibit UII-induced MAPK phosphorylation in CHO cell transfected with hUT, suggesting an anti-inflammatory role (Clozel et al., [@B18]). In animal models, it did not have any significant effect on renal blood flow or serum sodium concentration, nor did it change the mean arterial pressure, heart rate, or mean renal blood flow (Clozel et al., [@B18]). However, in a rat model of renal ischemia, palosuran prevented both postischemic renal vasoconstriction and reduced postischemic acute renal failure. It attenuated both the decreased tubular sodium reabsorption and the increased fractional excretion of sodium. It also significantly decreased tubulointerstitial lesions, decreasing the severity of changes (Clozel et al., [@B18]). Palosuran improved renal dysfunction and injury induced ischemia, revealing not only a role of UII in the pathogenesis of ischemia in acute renal failure, but also an opportunity for treatment in humans. However, its lack of effect on systemic blood flow suggests it is local to the kidneys. In addition, Clozel et al. ([@B18]) stated that the binding affinity of palosuran to the rat UT in intact CHO cell is very low \[IC~50~(μM) \> 10\], yet they administered palosuran in a dose of 10 mg/(kg h) resulting in a plasma concentration of approximately 5 μM (Tölle and van der Giet, [@B99]). Interestingly, this concentration was not able to inhibit rat UT *in vitro*, but showed efficacy *in vivo* in rat.

In a follow-up study, Clozel et al. ([@B19]) investigated the effect of a 25-week oral treatment of palosuran (300 mg/kg/day) in diabetic rats. Rats were treated with streptozocin (STZ), as it destroys pancreatic β-cells and results in insulin-sensitive hyperglycemia and associated complications, to establish a model of type 1 diabetes. Treatment with palosuran more than doubled the number of diabetic rats that survived. Palosuran halved the increase in cholesterol and largely prevented the increase in triglycerides. It also increased glucose tolerance, increased insulin levels and slowed the increase in glycemia, and glycosylated hemoglobin. This results in a delayed development of proteinuria and renal damage (Clozel et al., [@B19]). The slowed progression of diabetes due to an increase in glucose tolerance and a decrease in proteinuria furthers the clinical possibilities of UII system blockade. However, the authors studied a model of type 1 diabetes, whereas UII-induced diabetes is known to be of type 2. Although both models represent an abnormal metabolism, type 1 diabetes is characterized by a lack of insulin due to the autoimmune destruction of β-cells, and type 2 represents insulin resistance and deficiency. Also, the authors studied yet again the effects of UII antagonism in rat, where the binding affinity of palosuran is very low, and administered a palosuran regimen similar to the previous study, where plasma concentrations should be below efficacy.

In the first palosuran study on humans, Sidharta et al. ([@B85]) treated patients of both sexes afflicted by hypertension and diabetic nephropathy with 125 mg palosuran twice daily for 13.5 days. There were no significant changes in renal function parameters such as GFR, renal blood flow, and filtration fraction. However, within the 13.5 days of treatment, the 24-h urinary albumin excretion rate was significantly decreased by approximately 24% in comparison to baseline. Although the relationship between the 24-h urinary albumin excretion rate and the effect on renal function has not been completely elucidated, it is accepted as a clinical marker of cardiorenal disease (de Zeeuw, [@B22]; Lane, [@B55]; Brantsma et al., [@B14]). Therefore, the authors of the study concluded that palosuran may improve the current treatment of diabetic nephropathy (Sidharta et al., [@B85]). However, there are several concerns with the study, including the very low number of patients treated (*n* = 19), and the lack of a suitable control group that was not treated. In addition, for ethical reasons, the patients enrolled in the trial did not discontinue the use of medications such as angiotensin-converting enzyme inhibitors and angiotensin receptor blockers which are known to reduce macroalbuminuria. Therefore, the considerable reduction in urinary albumin secretion cannot be attributed to palosuran alone, as possible drug-drug interactions could rather be the cause. Interestingly, 7 months before Sidharta et al. ([@B85]) published their paper, Actelion Pharmaceuticals, the manufacturer of palosuran, declared that efficacy data from three individual proof-of-concept studies did not support a full-fledged clinical trial of on the indication of diabetic nephropathy (Desai et al., [@B24]).

Nevertheless, Sidharta et al. ([@B84]) later published a second paper on palosuran's effect on patients with type 2 diabetes. Although the authors had previously concluded that more patients and different dosing regimens should be used in future studies, they used approximately the same number of patients (*n* = 20) and the same dosing regimen (125 mg twice daily). To evaluate β-cell function, a hyperglycemic glucose clamp was applied (DeFronzo et al., [@B23]; Elahi, [@B33]) and the second-phase insulin response was chosen as the primary efficacy end-point. Palosuran did not affect the second-phase insulin response, nor did it affect the first-phase response. No effects on the glucose infusion rate were observed during the treatment. β-Cell secretory capacity was also assessed with a meal tolerance test and was found to be unchanged with palosuran. They also investigated insulin sensitivity without finding differences between palosuran and vehicle-treated groups. They concluded that palosuran did not have an influence on insulin secretion, insulin sensitivity or glucose levels in patients with type 2 diabetes treated with palosuran (Sidharta et al., [@B84]). It could be hypothesized that the exposure to palosuran was too low to invoke an effect, yet it was enough to alter urinary albumin secretion in their previous study.

This can be explained, not only by the concomitant medication used by patients in their first study, but also by palosuran's important ability to bind albumin. In fact, palosuran has recently been identified as a somatostatin receptor antagonist (Malagon et al., [@B65]) which is known to lower both glucose and albuminuria levels in diabetic models (Segev et al., [@B82]; Strowski et al., [@B93]). Therefore, the palosuran concentration may indeed have been too low to inhibit the UII system. The regimen of 125 mg of palosuran twice daily used by Sidharta et al. ([@B85]) results in a peak plasma concentration (*C*~max~ ≤ 260 nM) that is ≥10-fold lower than the UT affinity of palosuran determined by Behm et al. ([@B6]). In fact, it is an underestimation as it assumes that palosuran concentrations stay constant and that there are no native ligands (i.e., hUII, URP) to compete for UT occupancy. With these factors considered, the Schild analysis suggests that significant UT antagonism would only be observed at ≈200 μM palosuran, a concentration clearly never attained with a 125-mg dosing regimen (Behm et al., [@B6]). In addition to the *in vivo* palosuran studies, the *in vitro* studies also seem to have been under-treated. As mentioned previously, both studies by Clozel (Clozel et al., [@B18], [@B19]) administered approximately half the amount of palosuran necessary for efficacy. The observation of beneficial effects in the rat under these circumstances suggests a lack of UT affinity and an "off-target" effect of palosuran (Behm et al., [@B6]). In fact, the initial study defining palosuran affinity and selectivity by Clozel et al. ([@B18]), as they have not specified, may or may not have randomized their tissue samples. Randomization is imperative in minimizing "reactivity bias" producing apparent, yet erroneous, results.

Therefore, caution must be used when interpreting data generated with the use of palosuran as it is not an optimal pharmacological tool. It interacts poorly with "non-human" UT receptors and losses affinity in intact cell and tissue-based assays. In addition, several actions of palosuran cannot be replicated using the alternative antagonist SB-710411 (Albertin et al., [@B1]; Spinazzi et al., [@B92]). However, results obtained with more reliable UT receptor antagonists, such as urantide and SB-611812, have demonstrated positive health effects that should be explored further. Although a clinical equivalent is no yet ready for commercial use, further research should be conducted on the matter as it has promise.

Piperazino-isoindolinone based antagonist
-----------------------------------------

Most recently, Johnson and Johnson discovered a non-peptide UII antagonist based on the piperazino-isoindolinone scaffold. The structure 7a exhibits single-digit nanomolar potencies in the rat FLIPR assay (IC~50~ = 1.0 nM) and in the hUT binding assay (*K*~i~ = 4.0 nM). It also exhibits potent antagonism in the human calcium flux assay (IC~50~ = 8.0 nM). 7a Blocks the effects of UII with 74% inhibition at 100 nM in the *in vitro* rat aortic ring assay. *In vivo*, in a rat ear-flush model, it reverses the increased ear pinna temperature induced by UII at 10 mg/kg. The 7a compound binds strongly and specifically to the human UII receptor, but its oral bioavailability could be improved upon (Lawson et al., [@B58]). Nevertheless, this new compound presents interesting research opportunity for treatment.

Conclusion
==========

Although only some 12 years have passed since UII receptor has been identified, the UII system has been shown as a major contributor to cardiovascular diseases, metabolic syndrome, and renal diseases. It seems that all three disease states are inter-related through several mechanisms and share a catalyst in the poor lifestyle choices of many in the Western world. Inhibition of the UII system has been studied with UT receptor antagonists with positive results on health in experimental animals, although a potent and safe antagonist that can be used in human is yet to be found.
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